Balyasny Asset Management
IRWD icon

Balyasny Asset Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Balyasny Asset Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$436K – 2830
2024
Q1 		$436K Sell
50,000
-325,000
-87% -$3.94M ﹤0.01% 2104
2023
Q4 		$4.29M Buy
+375,000
New +$3.71M 0.01% 1169

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management's IRWD Position: Q1 2026 in Review

Balyasny Asset Management sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2026, closing a stake of 65,156 shares — an estimated $220K sold.

Balyasny Asset Management first reported a position in IRWD in Q1 2018 and held it in 15 quarters. The position peaked at $18M in Q2 2023. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Balyasny Asset Management reported no remaining Ironwood Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 65,156 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $220K.
  • Balyasny Asset Management first reported a position in Ironwood Pharmaceuticals in Q1 2018 and held it in 15 quarters.
  • Balyasny Asset Management's Ironwood Pharmaceuticals position peaked at $18M in Q2 2023.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.